100 related articles for article (PubMed ID: 22617189)
1. It is all about heart rate. Or is it?
Sarraf M; Francis GS
J Am Coll Cardiol; 2012 May; 59(22):1946-7. PubMed ID: 22617189
[No Abstract] [Full Text] [Related]
2. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
3. Heart failure and COPD: time to SHIFT?
Sanders-van Wijk S; van Empel V; Knackstedt C; Brunner-La Rocca HP
Int J Cardiol; 2014 Mar; 172(2):293-4. PubMed ID: 24452222
[No Abstract] [Full Text] [Related]
4. [Ivabradine -- a novel approach for heart rate lowering].
Er F; Hoppe UC
Dtsch Med Wochenschr; 2005 Jun; 130(24):1501-2. PubMed ID: 15942839
[No Abstract] [Full Text] [Related]
5. Elevated heart rate proven to increase coronary events.
Fox K; Steg PG
Cardiovasc J Afr; 2008; 19(5):276-8. PubMed ID: 18997992
[No Abstract] [Full Text] [Related]
6. Ivabradine for systolic heart failure.
Meade CM; Clements JN
JAAPA; 2018 Mar; 31(3):52-54. PubMed ID: 29470374
[TBL] [Abstract][Full Text] [Related]
7. SHIfT: Ivabradine's additional clinical benefits regardless of background beta-blocker dose.
Cardiovasc J Afr; 2012 Jul; 23(6):360. PubMed ID: 23961539
[No Abstract] [Full Text] [Related]
8. Ivabradine in Severe Aortic Stenosis with Poor Left Ventricular Ejection Fraction.
Huang D; Chan PH; Lam CC; Shea PC; Yiu KH; Tse HF; Siu CW
J Heart Valve Dis; 2015 Jul; 24(4):433-5. PubMed ID: 26897811
[TBL] [Abstract][Full Text] [Related]
9. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
[TBL] [Abstract][Full Text] [Related]
10. Differential impacts of achieved heart rate and achieved dose of β-blocker on clinical outcomes in heart failure with and without atrial fibrillation.
Kato N; Kinugawa K; Teruhiko I; Hironori M; Hisataka M; Toshiro I; Masaru H; Atsushi Y; Nagai R
Int J Cardiol; 2014 May; 173(2):331-3. PubMed ID: 24680244
[No Abstract] [Full Text] [Related]
11. Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure.
Hamaad A; Lip GY; Nicholls D; MacFadyen RJ
Cardiovasc Drugs Ther; 2007 Dec; 21(6):437-44. PubMed ID: 17896170
[TBL] [Abstract][Full Text] [Related]
12. [Is heart rate adequately controlled in chronic systolic heart failure patients in Germany? results from a nationwide survey (INDICATE)].
Zugck C; Martinka P; Stöckl G; Tschöpe C; Störk S
Dtsch Med Wochenschr; 2015 Mar; 140(5):e48-55. PubMed ID: 25734683
[TBL] [Abstract][Full Text] [Related]
13. Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?
Porapakkham P; Porapakkham P; Krum H
Cardiovasc Ther; 2010 Apr; 28(2):93-100. PubMed ID: 20398098
[TBL] [Abstract][Full Text] [Related]
14. Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
Albert NM
Crit Care Nurse; 2007 Dec; 27(6):62-72. PubMed ID: 18032686
[No Abstract] [Full Text] [Related]
15. Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction--data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry.
Martínez-Sellés M; Datino T; Alhama M; Barrueco N; Castillo I; Fernández-Avilés F
J Cardiovasc Med (Hagerstown); 2010 May; 11(5):352-8. PubMed ID: 20154635
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine: a ray of hope for inappropriate sinus tachycardia.
Scheinman MM; Vedantham V
J Am Coll Cardiol; 2012 Oct; 60(15):1330-2. PubMed ID: 22981552
[No Abstract] [Full Text] [Related]
17. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
18. [Coronary heart disease. Rapid heart rate has an unfavorable prognosis].
Einecke D
MMW Fortschr Med; 2008 Sep; 150(38):12-4. PubMed ID: 18983046
[No Abstract] [Full Text] [Related]
19. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
Vizzardi E; Bonadei I; D'Aloia A; Del Magro F; Piovanelli B; Bontempi L; Curnis A; Dei Cas L
Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
[TBL] [Abstract][Full Text] [Related]
20. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.
Busseuil D; Shi Y; Mecteau M; Brand G; Gillis MA; Thorin E; Asselin C; Roméo P; Leung TK; Latour JG; Des Rosiers C; Bouly M; Rhéaume E; Tardif JC
Cardiology; 2010; 117(3):234-42. PubMed ID: 21212673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
